Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

ARIAD Pharmaceuticals Shares Plunged: What You Need to Know

By Travis Hoium – Updated Apr 6, 2017 at 10:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Is this meaningful? Or just another movement?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: ARIAD Pharmaceuticals (Nasdaq: ARIA) shares dropped 10% in trading Tuesday.

So what: A day after shares popped, the company announced a stock offering at $3.70 per share. The company will sell 16 million shares and net $59.2 million before fees.

Now what: The cash will be used to fund a trial of oral ponatinib, which the company hopes to bring to the market. This is disappointing after yesterday's bump, but the offering will provide enough cash to fund operations into 2012. I am more cautious about this news today because the offer price was lower than yesterday's close and dilutes current shareholders.

Interested in more info on ARIAD Pharmaceuticals? Add it to your watchlist by clicking here.

Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings, or follow his Motley Fool CAPS picks at TMFFlushDraw.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Tritium DCFC Limited (DCFC) Q4 2022 Earnings Call Transcript

IBEX Limited (IBEX) Q4 2022 Earnings Call Transcript

Japan's Government Intervened to Prop Up the Yen

Amazon's Thursday Night Football Broadcast Comes With One Major Exclusion

Credit Suisse Looks to Skinny Down to Move Forward

Motley Fool Returns

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns

339%

S&P 500 Returns

109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.